       Document 0147
 DOCN  M9640147
 TI    In vitro and in vivo enhancement of ddI activity against Rauscher murine
       leukemia virus by ribavirin.
 DT    9604
 AU    Allen LB; Quenelle DC; Westbrook L; Taylor BA; Prichard MN; Brazier AD;
       Hollingshead MG; Shannon WM; Microbiology Research Department, Southern
       Research Institute,; Birmingham, AL 35205, USA.
 SO    Antiviral Res. 1995 Jun;27(3):317-23. Unique Identifier : AIDSLINE
       MED/96145339
 AB    Ribavirin has been reported to enhance the activity of ddI against HIV.
       We explored this enhancement of antiviral activity in Rauscher murine
       leukemia virus (RMuLV) models in vitro and in vivo. The significant
       finding in these studies was that combinations of the drugs exhibited
       virus titer reductions that were greater than would be expected if the
       drug interactions were simply additive. These effects were designated
       synergistic by the method of Prichard and Shipman (Prichard, M.N. and
       Shipman, C., Jr. (1990). A three-dimensional model to analyze drug-drug
       interaction, Antiviral Res. 14, 181-206). In addition to the antiviral
       synergy, we also observed some synergistic toxicity in the animal model.
 DE    Animal  Cell Line  Didanosine/*PHARMACOLOGY  Drug Synergism  Leukemia,
       Experimental/*DRUG THERAPY/VIROLOGY  Male  Mice  Rauscher Virus/*DRUG
       EFFECTS/ISOLATION & PURIF  Retroviridae Infections/*DRUG THERAPY
       Ribavirin/*PHARMACOLOGY  Support, U.S. Gov't, P.H.S.  Tumor Virus
       Infections/*DRUG THERAPY  Weight Gain  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

